Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis

Table 1 Developement period of reported cases of hepatocellular carcinoma associated with autoimmune hepatitis and primary biliary cirrhosis, compared to cases of general hepatocellular carcinoma in Japan

Clinical status	Compiled numbers			P-values
	HCC patients with AIH (AIH-series)	HCC patients with PBC (PBC-series)	General-HCC patients	AIH-series/General-HCC patients	PBC-series/General-HCC patients	AIH-series/PBC-series
Observation period (mean ± SD)	Total: 38 1 yr 1 mo-23 yr (10 yr 6 mo ± 6 yr 7 mo)	Total: 49 3 mo-24 yr (9 yr 4 mo ± 6 yr 4 mo)
			NA	NA	NA	P = 0.307
						(P = 0.815)
Interval between liver damage and HCC diagnosis (mean ± SD)	Total: 34	Total: 40
	0-22 yr 9 mo	0-24 yr	NA	NA	NA	P = 0.740
	(10 yr 2 mo ± 6y 5 mo)	(9 yr 9 mo ± 7 yr 0 mo)				(P = 0.688)
Period from HCC development to death (mean ± SD)	Total: 18	Total: 16
	2 mo-3 yr	0-5 yr	NA	NA	NA	P = 0.047a
	(1 yr 2 mo ± 12 mo)	(8.4 ± 14 mo)				(P = 0.401)

The P-value above was calculated from the Mann-Whitney U-test and the P-value below, indicated in parentheses, was calculated from the F-test.

^aP < 0.05, Statistically significant. HCC: Hepatocellular carcinoma; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; SD: Standard deviation; NA: Not available.